The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2018 | MRD evaluation in clinical practice for MM
Measurable residual disease (MRD) is evaluated and analyzed in clinical trials, but less attention is currently given to it in practice, particularly in elderly patients, even those fit enough for transplant. Speaking from the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Elena Zamagni, MD, PhD, from the University of Bologna, Bologna, Italy, points out that although there are a number of difficulties involving combining imaging techniques to analyze MRD, it may help increase the success of treatment regimens and can help determine which course of treatment is best.
